NRX Pharmaceuticals, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.1M | $983.0K | $242.0K | $0 | $0 | $0 |
| Cost of Revenue | $675.0K | $631.0K | $408.0K | $97.0K | $0 | $0 | $0 |
| Gross Profit | $426.0K | $437.0K | $575.0K | $145.0K | $0 | $0 | $0 |
| Gross Margin | 38.7% | 40.9% | 58.5% | 59.9% | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $2.1M | $1.3M | $557.0K | $1.4M | $987.0K | $804.0K | $611.0K |
| SG&A Expense | $4.7M | $3.8M | $4.6M | $2.8M | $2.7M | $2.9M | $2.4M |
| Operating Income | $-6.5M | $-4.7M | $-4.6M | $-4.0M | $-3.7M | $-3.8M | $-3.0M |
| Operating Margin | -590.8% | -444.0% | -470.3% | -1,662.8% | — | — | — |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | — | — | $0 | $0 | — |
| Net Income | $-16.5M | $-1.4M | $361.0K | $-5.9M | $-17.6M | $-5.5M | $-1.6M |
| Net Margin | -1,500.5% | -133.9% | 36.7% | -2,433.9% | — | — | — |
| EPS (Basic) | $-0.44 | $-0.04 | $0.25 | $-0.14 | $-0.49 | $-0.17 | $-0.08 |
| EPS (Diluted) | — | — | — | — | — | — | — |
| Shares Outstanding (Basic) | 37.6M | 32.3M | 21.4M | 44.5M | 35.9M | 32.8M | 21.9M |
| Shares Outstanding (Diluted) | 37.6M | 32.3M | 21.4M | 44.5M | 35.9M | 32.8M | 21.9M |
| Dividends Per Share | — | — | — | — | — | — | — |